<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025519</url>
  </required_header>
  <id_info>
    <org_study_id>FCCC-01006</org_study_id>
    <secondary_id>CDR0000068970</secondary_id>
    <secondary_id>TUHSC-3721</secondary_id>
    <secondary_id>NCI-G01-2021</secondary_id>
    <nct_id>NCT00025519</nct_id>
  </id_info>
  <brief_title>Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer</brief_title>
  <official_title>Submyeloablative Allogeneic Blood Stem Cell Transplantation With HLA Identical Donor Lymphocyte Infusions From Matched Related and Matched Unrelated Donors for Treatment of Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were&#xD;
      destroyed by chemotherapy and radiation therapy used to kill cancer cells. Sometimes the&#xD;
      transplanted cells can be rejected by the body's tissues. Mycophenolate mofetil, tacrolimus,&#xD;
      and donor white blood cells may prevent this from happening.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by peripheral&#xD;
      stem cell transplantation in treating patients who have metastatic or recurrent kidney&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of submyeloablative HLA-identical allogeneic peripheral blood&#xD;
           stem cell transplantation in patients with metastatic or recurrent renal cell carcinoma.&#xD;
&#xD;
        -  Determine the toxicity of this regimen, in terms of incidence and severity of graft&#xD;
           rejection, acute graft-vs-host disease (GVHD), chronic GVHD, adverse effects from the&#xD;
           preparative regimen and thalidomide, and infection and bleeding, in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this regimen, in terms of objective partial and complete&#xD;
           response rates, in these patients.&#xD;
&#xD;
        -  Determine the engraftment rates and extent of chimerism in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the overall survival and time to treatment failure rate in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the impact of thalidomide on the treatment of chronic GVHD in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to risk (low vs high).&#xD;
&#xD;
      Patients receive fludarabine IV over 30 minutes once daily on days -4 to -2 followed by total&#xD;
      body irradiation on day -1. Patients receive tacrolimus IV over 24 hours or orally daily on&#xD;
      days -3 to 35 and oral mycophenolate mofetil twice daily on days -3 to 28 as graft-vs-host&#xD;
      disease (GVHD) prophylaxis. Patients undergo allogeneic peripheral blood stem cell&#xD;
      transplantation over 1-2 hours on day 0.&#xD;
&#xD;
      Patients maintaining a mixed chimerism with no evidence of grade III or IV GVHD receive donor&#xD;
      lymphocyte infusions (DLI) on days 60, 90, and 120. Patients may receive additional DLI as&#xD;
      needed. Patients with limited chronic GVHD receive oral thalidomide daily beginning after day&#xD;
      80 and continuing for 1 year or until disease progression or resolution of chronic GVHD.&#xD;
&#xD;
      Patients are followed at 1, 3, 6, and 12 months and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 20-40 patients (10-20 per stratum) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma (RCC)&#xD;
&#xD;
               -  Histology demonstrates major clear cell component&#xD;
&#xD;
               -  Metastatic (stage IV) or recurrent disease&#xD;
&#xD;
          -  Prior debulking nephrectomy required&#xD;
&#xD;
               -  Disease not amenable to complete surgical resection&#xD;
&#xD;
          -  Must have HLA-identical donor&#xD;
&#xD;
               -  Matched related sibling donors must have 6/6 serologic HLA A, B, and DR match&#xD;
                  with molecular confirmation at DRB1&#xD;
&#xD;
                    -  A 5/6 serologic mismatch with one antigen mismatch at locus A or B (not DR)&#xD;
                       with molecular confirmation at locus A, B, and DRB1 allowed&#xD;
&#xD;
               -  Matched unrelated donors must have a minimum of 8 out of 10 molecular matches at&#xD;
                  loci A, B, C, DRB1, and DQB1&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
               -  Negative MRI required&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100% OR&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT/AST less than 2 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase less than 2 times ULN&#xD;
&#xD;
          -  Hepatitis A, B, and C negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
          -  Calcium less than 10.5 mg/dL (bisphosphonates allowed)&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF no less than 10% below lower limit of normal&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1 and DLCO greater than 50%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active bacterial, fungal, or viral (including cytomegalovirus) infections&#xD;
&#xD;
          -  No intolerance or allergy to tacrolimus, mycophenolate mofetil, or fludarabine&#xD;
&#xD;
          -  No intolerance to 200 cGy of total body irradiation&#xD;
&#xD;
          -  No other serious comorbid disease, neurologic condition, or psychosocial condition&#xD;
             that would preclude study follow-up&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for at least 1 month before, during,&#xD;
             and for at least 3 months after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior interleukin-2 allowed&#xD;
&#xD;
          -  Prior interferon alfa allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior chemotherapy allowed&#xD;
&#xD;
          -  No other concurrent chemotherapy for RCC&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids for other comorbid disease&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior extensive radiotherapy to marrow microenvironment greater than 20% of total&#xD;
             marrow mass&#xD;
&#xD;
          -  No prior radiotherapy that has reached tissue tolerance for heart, lung, liver,&#xD;
             kidney, or spinal cord&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent therapy for RCC&#xD;
&#xD;
          -  No concurrent enrollment on another investigational protocol for treatment of RCC&#xD;
&#xD;
          -  No other concurrent immunosuppressive medications&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary R. Hudes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 10, 2013</last_update_submitted>
  <last_update_submitted_qc>July 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

